Clinical Trial Update: Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of radiotherapy, tislelizumab, and irinotecan for mismatch repair-proficient, microsatellite stable metastatic colorect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Microsatellite Stability

Drugs mentioned

• Irinotecan (Irinotecan)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Mismatch Repair-proficient, Colorectal Cancer Metastatic | Phase 2 | Status: UNKNOWN